A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
- 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2017 Results from this and one other study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 19 May 2017 According to a PharmaMar media release, data from this trial will be presented at the 53rd Congress of the American Society of Clinical Oncology (ASCO) 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History